Keros Therapeutics Inc.

KROS | NASDAQ

Price Alert Chart Builder DCF Calculator

$11.71

+$0.23 (+2.00%)

Sep 22, 2026, 11:47 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.00%

(1D)

Rating

Updated: Sep 12, 2026

44.5

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $232.16M

1D Range

11.52 11.79

52W Range

9.69 22.55

Valuation (TTM)

PE -3.57

PB 0.87

EV/EBITDA 0.17

Valuation (NTM)

Forward PE N/A

Forward PEG -0.25

Price Target $20.33

Cash Flow

FCF Yield -21.3%

SBC Adj. FCF Yield -31.4%

SBC Impact -47.2%

Margins

Gross Margin 94.7%

Operating Margin -675.8%

FCF Margin -322.9%

Growth (CAGR)

Revenue 3Y | 5Y 8.9% | 172.5%

Dil EPS 3Y | 5Y 38.8% | 14.0%

FCF 3Y | 5Y 103.5% | 29.9%

Returns

ROA -28.9%

ROE -21.4%

ROIC -35.3%

Financial Health

Net Cash

$241.88M

Current Ratio 21.96

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and...

Sector Healthcare

Industry Biotechnology

Employees 92

IPO Date Apr 7, 2020

Website www.kerostx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 4, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$20

Upside

+70.79%

Buy (3)

Hold (2)

Sell (0)

Analyst Details ➞